Search Bar & Filters
Found 58 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.
Actively Recruiting
Researchers are studying the use of unlicensed cryopreserved cord blood units CBUs for transplantation in both children and adults with blood cancers and other related disorders. This observational study involves patients with hematologic malignancies and various inherited and acquired disorders affecting the blood and immune system. The main goal is to monitor how well neutrophil recovery occurs after transplantation using these unlicensed CBUs in multiple institutions. Participants receive unlicensed cryopreserved CBUs as part of their transplant treatment. The study includes patients of any age receiving these CBUs for approved indications. The protocol focuses on the access and distribution of these unlicensed units rather than a specific treatment intervention. The study gathers data from recipients who receive these CBUs, tracking outcomes after transplantation. Participants are monitored for neutrophil recovery at 60 and 100 days after transplant, defined by a neutrophil count of at least 500mm3. Researchers also collect information on infection transmission, infusion reactions, survival rates at one year, and incidence of acute and chronic graft versus host disease. Platelet recovery is also evaluated. Safety and efficacy outcomes are followed over time to better understand the effects of unlicensed CBUs in this patient population.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how cannabis use affects the quality of life in patients with multiple myeloma who are receiving chemotherapy. This observational study compares patients who use cannabis with those who do not, aiming to understand both potential benefits and harms. It uses specific tools like the Functional Assessment of Cancer Therapy-Multiple Myeloma FACT-MM and patient-reported symptoms to assess these effects over time. Participants are divided into two groups one group completes surveys and provides blood samples throughout the study, and the other group consists of healthcare providers who complete a survey related to the study. The study follows participants for up to one year, focusing on longitudinal patterns in quality of life and the potential therapeutic benefits and adverse effects associated with cannabis use. During the study, patients complete questionnaires and provide blood samples regularly. Researchers monitor their symptoms and any side effects using standardized scales such as the Edmonton Symptoms Assessment Scale and Common Terminology Criteria for Adverse Events. The study tracks changes over time to better understand how cannabis use interacts with cancer-directed treatments and overall patient well-being.
Actively Recruiting
Researchers are evaluating the safety, tolerability, how the body processes and responds to BGB-B2033, and its preliminary antitumor activity in adults with advanced or metastatic cancers including hepatocellular carcinoma, alpha-fetoprotein-producing gastric cancer, extragonadal yolk sac tumors, non-dysgerminomas, and glypican-3-positive squamous non-small cell lung cancer. The study aims to find the recommended dose for further research when BGB-B2033 is given alone or combined with tislelizumab, with or without bevacizumab. Participants will receive BGB-B2033 through intravenous infusion either alone or combined with tislelizumab and sometimes bevacizumab. The study includes several parts dose escalation and safety expansion of BGB-B2033 alone, combination treatments to determine safe doses and recommended doses for expansion, and dose expansion in specific groups including participants with hepatocellular carcinoma in Asia and the United States. During the study, participants will have regular assessments to monitor safety, side effects, how their body processes BGB-B2033, and whether their cancer responds to treatment. Researchers will track adverse events, the best dose, overall response rates, duration of response, disease control, progression-free survival, serum drug levels, and overall survival for up to about two years. Participants will be closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating TER-2013 in patients with advanced solid tumors that have changes in the AKTPI3KPTEN pathway. This Phase 12 open-label study aims to assess the safety, tolerability, how the body processes the drug, and its anti-tumor activity. The trial includes patients with metastatic or locally advanced tumors that cannot be removed by surgery and who have limited treatment options. The study has two parts Dose Escalation and Dose Expansion. Participants receive TER-2013 either alone or combined with fulvestrant, a hormone therapy. The TER-2013 is given orally as capsules or tablets, while fulvestrant is given as a 500 mg injection into the muscle. The dose escalation part determines the maximum tolerated dose, and the expansion part evaluates preliminary clinical activity at the recommended dose. Participants will undergo evaluations including physical exams, tumor scans assessed by RECIST v1.1 criteria, and blood tests to monitor drug levels and effects. Researchers track side effects, response to treatment, and survival for up to two years. The study measures how well TER-2013 is tolerated, its activity against tumors, and its effects on pharmacokinetics and pharmacodynamics. The total duration of participation varies depending on treatment and follow-up.
Actively Recruiting
Researchers are studying the effects of AZD0120, an autologous dual-targeting CAR-T therapy aimed at BCMA and CD19, compared with autologous stem cell transplant ASCT in people newly diagnosed with multiple myeloma who are eligible for transplant. This open-label, randomized Phase III trial aims to measure progression-free survival and the rate of minimal residual disease negative complete response over up to 13 years. Participants are assigned to one of two treatment groups. Arm A receives lymphodepletion with cyclophosphamide and fludarabine over three days, followed by a single infusion of AZD0120 CAR-T cells, then up to two years of lenalidomide maintenance therapy. Arm B receives high-dose melphalan conditioning for 24 to 48 hours followed by ASCT and then the same lenalidomide maintenance regimen for up to two years. The study includes a long-term follow-up period lasting up to 15 years after the last AZD0120 infusion. Throughout the study, participants undergo regular monitoring, including assessments of disease progression and response according to established criteria. Researchers evaluate outcomes such as progression-free survival, complete and overall response rates, duration of response, and safety over approximately 13 years. Participants may expect study visits and evaluations aligned with treatment and follow-up schedules to track their health and treatment effects during this extended period.
Actively Recruiting
This trial investigates treatments for adults with relapsed or refractory multiple myeloma who have already received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. Researchers are comparing the effects of a new drug called JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody called teclistamab. The goal is to evaluate how well JNJ-79635322 works in comparison to the existing antibody treatment. Participants will be randomly assigned to receive either JNJ-79635322 or teclistamab, both given as subcutaneous injections. Treatments will continue until the disease progresses or participants experience intolerable side effects. The study is designed as a phase 3 trial, with treatment lasting potentially up to several years depending on individual response and tolerance. During the trial, participants will have regular assessments to monitor response to treatment, disease progression, side effects, and quality of life. Measures include overall response, progression-free survival, complete response rates, symptom and functioning questionnaires, and laboratory tests. Safety is closely monitored, along with drug levels and immune responses. The total participation period may last up to five years and seven months, with ongoing evaluations throughout this time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
Researchers are studying the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo with CDK46i and letrozole. This study focuses on adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. The trial is a phase III, randomized, double-blind, placebo-controlled study aiming to improve first-line treatment options for this condition. Participants will be randomly assigned to receive either oral inavolisib once daily alongside letrozole and a CDK46 inhibitor or a matching placebo with letrozole and CDK46 inhibitor. The CDK46 inhibitor is given on either days 1-21 or days 1-28 of each 28-day treatment cycle. Both groups will follow this treatment regimen throughout the study period. During the trial, participants will be monitored regularly to assess progression-free survival, overall survival, and various measures of treatment response and quality of life, including pain and physical function. Safety will be closely tracked by recording adverse events and treatment-related symptoms using patient-reported outcomes. The study may last up to seven years, including long-term follow-up to evaluate the effects of the treatments over time.
Actively Recruiting
Researchers are evaluating multiple treatment combinations for people with metastatic or inoperable locally advanced breast cancer. This umbrella study includes several patient groups based on cancer type and prior treatments. The goal is to assess the safety and effectiveness of these combinations in different breast cancer subtypes, including triple-negative, hormone receptor-positive, and HER2-positive or HER2-low disease. Participants are assigned to various treatment arms depending on their cohort. Treatments include combinations of drugs such as atezolizumab, nab-paclitaxel, capecitabine, ipatasertib, and trastuzumab deruxtecan, among others. Some participants may continue to a second treatment stage if their cancer progresses or if side effects occur, provided they meet specific criteria. During the study, participants will have regular assessments including tumor measurements, biopsies for biomarker analysis, and lab tests to monitor health and treatment effects. Researchers will measure outcomes like the tumor response rate, progression-free survival, overall survival, and side effects over up to 12 years. Participants are monitored closely to track safety and treatment impact throughout the study.
1-10 of 58
1